4.7 Article

A role for coding functional variants in HNF4A in type 2 diabetes susceptibility

Journal

DIABETOLOGIA
Volume 54, Issue 1, Pages 111-119

Publisher

SPRINGER
DOI: 10.1007/s00125-010-1916-4

Keywords

HNF4A; Low-frequency variants; T130I; Type 2 diabetes; V255M

Funding

  1. Medical Research Council (MRC) [G0000934, 81696]
  2. Wellcome Trust [068545/Z/02, GR072960]
  3. Oxford NIHR Biomedical Research Centre
  4. Danish Agency for Science Technology and Innovation [271-06-0539]
  5. National Health Services in the counties of Copenhagen, Aarhus, Ringkobing, Ribe and South Jutland
  6. Danish Research Foundation for General Practice, Danish Centre for Evaluation and Health Technology Assessment
  7. National Board of Health
  8. Danish Medical Research Council
  9. Aarhus University Research Foundation
  10. Novo Nordisk Foundation
  11. Novo Nordisk
  12. Novo Nordisk Scandinavia
  13. Astra Denmark
  14. Pfizer Denmark
  15. GlaxoSmithKline Pharma Denmark
  16. Servier Denmark
  17. HemoCue Denmark
  18. US National Institutes of Health [DK062370, DK072193, HL084729, HG002651, U54 DA021519]
  19. National Human Genome Research Institute [1 Z01 HG000024]
  20. Academy of Finland
  21. EVO [5263]
  22. Sigrid Juselius Foundation
  23. Finnish Diabetes Research Foundation
  24. Folkhalsan Research Foundation
  25. EC [BM4-CT95-0662]
  26. Swedish Medical Research Council
  27. JDF Wallenberg Foundation
  28. Diabetes UK
  29. Medical Research Council [G0700222, G0000934] Funding Source: researchfish
  30. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL084729] Funding Source: NIH RePORTER
  31. NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002651, ZIAHG000024] Funding Source: NIH RePORTER
  32. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062370, R56DK062370, U01DK062370, R01DK072193] Funding Source: NIH RePORTER
  33. MRC [G0000934, G0700222] Funding Source: UKRI

Ask authors/readers for more resources

Aims/hypothesis Rare mutations in the gene HNF4A, encoding the transcription factor hepatocyte nuclear factor 4 alpha (HNF-4A), account for similar to 5% of cases of MODY and more frequent variants in this gene may be involved in multifactorial forms of diabetes. Two low-frequency, non-synonymous variants in HNF4A (V255M, minor allele frequency [MAF] similar to 0.1%; T130I, MAF similar to 3.0%)-known to influence downstream HNF-4A target gene expression-are of interest, but previous type 2 diabetes association reports were inconclusive. We aimed to evaluate the contribution of these variants to type 2 diabetes susceptibility through large-scale association analysis. Methods We genotyped both variants in at least 5,745 cases and 14,756 population controls from the UK and Denmark. We also undertook an expanded association analysis that included previously reported and novel genotype data obtained in Danish, Finnish, Canadian and Swedish samples. A meta-analysis incorporating all published association studies of the T130I variant was subsequently carried out in a maximum sample size of 14,279 cases and 26,835 controls. Results We found no association between V255M and type 2 diabetes in either the initial (p = 0.28) or the expanded analysis (p = 0.44). However, T130I demonstrated a modest association with type 2 diabetes in the UK and Danish samples (additive per allele OR 1.17 [95% CI 1.08-1.28]; p = 1.5 x 10(-4)), which was strengthened in the meta-analysis (OR 1.20 [95% CI 1.10-1.30]; p = 2.1 x 10(-5)). Conclusions Our data are consistent with T130I as a low-frequency variant influencing type 2 diabetes risk, but are not conclusive when judged against stringent standards for genome-wide significance. This study exemplifies the difficulties encountered in association testing of low-frequency variants.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available